CRISPR Therapeutics CRSP
SwitzerlandHealthcare · BiotechnologyUSD
87.56 USD (+67.3%)
18 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
CRISPR Therapeutics is a biotechnology company developing gene therapies based on CRISPR/Cas9 technology to treat genetic and oncological diseases.
Key points
from its scores- ✓Strong growth10.0
- ✕Poor share-price trend0.5
- ✕Little competitive advantage0.7
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHold in portfolio only for investors with high risk tolerance and a long-term horizon, pending clinical and regulatory milestones.
CRISPR Therapeutics is a biotechnology company in the development phase, with no revenue from approved products and very negative profitability (operating margin of -1127.55%). Its revenue growth is exceptional (1041.40%), but the valuation is very demanding (FCF yield of -4.26%) and the risk is high.
The main risk is the dependence on regulatory approval of its gene therapies, a long and highly uncertain process that can delay or prevent revenue generation.
Context and risks
CRISPR Therapeutics operates in Switzerland, with a moderate regulatory and governance framework. The main risk is the dependence on regulatory approval of its gene therapies, a long process with high uncertainty. The company has no revenue from approved products, so its valuation depends on future clinical and regulatory milestones.
Is CRISPR Therapeutics stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 10,961% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 2.9 | 4.1 | −29% |
| Price / sales | 378.0 | 3.4 | +10,961% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 87.56 USD, +67.3% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 0.7 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −15.0
- EV / EBITDA
- −6.8
- Price / book
- 2.9
- Price / sales
- 378.0
- Market cap
- 5.1B USD
- Enterprise value
- 3.5B USD
Profitability
- ROE
- −26.1%
- ROA
- −14.2%
- ROIC (approx.)
- −6.0%
- Gross margin
- 0.0%
- Operating margin
- −1,127.6%
- Net margin
- 0.0%
- Free cash flow
- −215.8M USD
- FCF yield
- −4.3%
Solvency
- Total debt
- 783.7M USD
- Net debt
- −1.6B USD
- Cash
- 2.4B USD
- EBITDA
- −513.2M USD
- Net debt / EBITDA
- 3.08
- Debt / equity
- 44.87
- Current ratio
- 17.85
- Quick ratio
- 17.79
Growth
- Revenue growth
- +1,041.4%
- EPS (TTM)
- −4.74 USD
- EPS (forward)
- −3.50 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.76
- Analyst consensus
- Buy (18)
- Target price
- 87.56 USD
- 52-week range
- 44.12 – 78.48
Recent news
All CRSP news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about CRISPR Therapeutics
Is CRISPR Therapeutics stock cheap or expensive?
On Price / sales, it trades 10,961% above the Healthcare median. Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 87.56 USD, +67.3% versus the price. This is not investment advice.
What score does CRISPR Therapeutics get on MeridIAn Screener?
It scores 2.7 out of 10, rank 2,099 of 2,130 (better than 1% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Momentum (0.5). Analysis of 08/10/2026.
How much is CRISPR Therapeutics worth on the stock market?
Its market capitalisation is 5.1B USD and its enterprise value, debt included, is 3.5B USD.
How much debt does CRISPR Therapeutics have?
It has more cash than debt: net cash of 1.6B USD.
Does CRISPR Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has CRISPR Therapeutics stock performed over the last year?
It has fallen 28.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 44.12 and 78.48 USD. Past performance does not guarantee future results.
What do analysts think of CRISPR Therapeutics?
18 analysts cover it; their average recommendation is “Buy” and their average target is 87.56 USD (+67.3% versus the price). It is an estimate, not market data.